Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
22.1.2025 14:05:00 CET | Business Wire | Press release
Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy.
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122884484/en/
Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas.
Key Highlights:
- Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, reflecting a global focus on advancing these therapies.
- Pipeline Insights: Solid tumors dominate OVT research, with trials targeting cancers such as melanoma, glioblastoma, and pancreatic cancer.
- Innovative Delivery Systems: Advances like nanoparticle systems and cell-based carriers address key challenges in targeting and delivery.
- Combination Therapies: Integration with immune checkpoint inhibitors, CAR-T therapies, and chemotherapy is enhancing the efficacy and scope of OVT.
- Regulatory Overview: Provides guidance on navigating complex global regulatory pathways, including insights into fast-tracking approvals.
This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122884484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestGorilla Launches New AI Readiness and AI Fluency Assessments to Help Companies Hire for the Skills That Matter Now3.3.2026 11:34:00 CET | Press release
Seven new AI assessments, built on TestGorilla's five-pillar AI Fluency Framework, give hiring teams a science-backed way to evaluate what resumes can no longer reveal. TestGorilla, the skills-based hiring platform trusted by thousands of organisations worldwide, today announced a suite of new assessments and simulation tests purpose-built to help talent acquisition teams evaluate AI readiness and AI fluency off the back of the company’s flagship event: Hire for the AI Era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303398545/en/ Use validated assessments and structured AI video interviews through the TestGorilla platform to measure different aspects of AI fluency across technical and non-technical roles. Inside the platform, tools are clearly labeled with AI fluency making it easy to find and build an assessment. The launch coincides with a crucial shift in the hiring landscape. TestGorilla co-founder and CEO Wouter
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance3.3.2026 11:19:00 CET | Press release
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery. Unlike traditional Extended Depth of Focus lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL - while preserving contrast sensitivity, visual quality, and minimizing side effects such as halos and glare, hallmarks of its patented fully refractive design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303823337/en/ Swiss Advanced Vision premium IOL lenses for cataract surgery A recent peer-reviewed study, Comparative Analysis of Visual Outcomes Between Lucidis 108M (EDOF) and PhysIOL BVI FineVision (Diffractive) IOLs Using Defocus Curve Measurements by H. Naftali, W. Nasser, and M. Naftali, provides compelling comparative data. The findings show that Lucidis® achieves a d
Türk Telekom and P.I. Works Announce Strategic Collaboration on AI-Driven 5G Network Slicing at MWC Barcelona3.3.2026 10:16:00 CET | Press release
Türk Telekom and P.I. Works today announced a strategic collaboration on AI-driven 5G network slicing assurance, unveiled during GSMA Mobile World Congress (MWC) Barcelona 2026. Türk Telekom has successfully trialed P.I. Works’ AI-powered 5G RAN Slice Assurance solution in Türk Telekom R&D Innovation & Test Center, strengthening its ability to deliver differentiated and performance-assured 5G services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303543772/en/ The solution is designed to ensure network slicing performance by enabling real-time monitoring of slice-level KPIs, early detection of performance degradations, and AI-assisted root cause analysis. With these capabilities, Türk Telekom aims to proactively manage service levels, and ensure consistent service continuity across different 5G slice types. Türk Telekom Ebubekir Şahin stated: “As we approach the 5G era, we continuously evolve our mobile network to deliv
BlackLine Brings BeyondTheBlack to Paris, Showcasing Innovation and Best Practice for Modern Finance Teams3.3.2026 10:00:00 CET | Press release
BlackLine, Inc. (Nasdaq: BL), the future-ready platform for the Office of the CFO, today announces BeyondTheBlack Paris, taking place on Thursday 25 June 2026 at 28 George V, Paris 8. BeyondTheBlack Paris will bring together finance and accounting leaders from across France and the wider EMEA region for a full day dedicated to finance transformation, industry best practice and peer-led learning. As part of BlackLine’s global BeyondTheBlack event series, the Paris event will focus on how finance teams can streamline operations, improve accuracy and unlock greater strategic value through automation and intelligence. The programme will feature keynote sessions from Owen Ryan, CEO of BlackLine, and Philippe Omer-Decugis, General Manager, EMEA, followed by a technology-focused session from Jeremy Ung, CTO, who will unveil exclusive major product announcements while examining the role of AI and innovation across finance and accounting. Attendees will also hear from partners and customers thr
BlackLine Announces BeyondTheBlack London, Bringing Finance Leaders Together to Shape the Future of the Office of the CFO3.3.2026 10:00:00 CET | Press release
BlackLine, Inc. (Nasdaq: BL), the future-ready platform for the Office of the CFO, today announces BeyondTheBlack London, taking place on Tuesday 14 April 2026 at the London Hilton on Park Lane. BeyondTheBlack is BlackLine’s award-winning event series, designed to bring finance and accounting leaders together to explore how modern teams can transform core financial processes, reduce manual work, and operate with greater accuracy, efficiency and intelligence. The London event will convene senior finance professionals, partners and BlackLine executives for a full day of learning, peer-led insight and networking. The agenda will open with plenary sessions from Owen Ryan, CEO of BlackLine, and Philippe Omer-Decugis, General Manager, EMEA, followed by a keynote from Jeremy Ung, CTO, who will share BlackLine’s latest thinking on AI, automation and innovation across the Office of the CFO. Morning sessions will also include an expert partner panel and guest keynote, before attendees move into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom